{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:51:36Z","timestamp":1768809096655,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T00:00:00Z","timestamp":1510099200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00280-017-3452-0","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T23:35:55Z","timestamp":1510097755000},"page":"89-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis"],"prefix":"10.1007","volume":"81","author":[{"given":"Ulrike","family":"Schmid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl-Heinz","family":"Liesenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angele","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Dallinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Freiwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,8]]},"reference":[{"issue":"12","key":"3452_CR1","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","volume":"68","author":"F Hilberg","year":"2008","unstructured":"Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68(12):4774\u20134782","journal-title":"Cancer Res"},{"issue":"3","key":"3452_CR2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1021\/jm501562a","volume":"58","author":"GJ Roth","year":"2015","unstructured":"Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, Wollin SL, Kaiser R (2015) Nintedanib: from discovery to the clinic. J Med Chem 58(3):1053\u20131063","journal-title":"J Med Chem"},{"issue":"1","key":"3452_CR3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40265-014-0335-0","volume":"75","author":"PL McCormack","year":"2015","unstructured":"McCormack PL (2015) Nintedanib: first global approval. Drugs 75(1):129\u2013139","journal-title":"Drugs"},{"issue":"2","key":"3452_CR4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ymthe.2006.01.017","volume":"14","author":"C Bouquet","year":"2006","unstructured":"Bouquet C, Lamande N, Brand M, Gasc JM, Jullienne B, Faure G, Griscelli F, Opolon P, Connault E, Perricaudet M, Corvol P (2006) Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen. Mol Ther 14(2):175\u2013182","journal-title":"Mol Ther"},{"issue":"2","key":"3452_CR5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","volume":"15","author":"M Reck","year":"2014","unstructured":"Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, Novello S (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15(2):143\u2013155","journal-title":"Lancet Oncol"},{"key":"3452_CR6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2016.10.011","volume":"102","author":"NH Hanna","year":"2016","unstructured":"Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, Voccia I, Pawel JV, Kovcin V, Agulnik J, Gaschler-Markefski B, Barrueco J, Sikken P, Schloss C, Kim JH (2016) Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Lung Cancer 102:65\u201373","journal-title":"Lung Cancer"},{"key":"3452_CR7","unstructured":"European Medicines Agency (2014) Committee for Medicinal Products for Human Use (CHMP) Assessment Report for Vargatef (nintedanib), 25 September 2014. \n                        http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002569\/WC500179972.pdf\n                        \n                    . Accessed 29 Aug 2017"},{"issue":"2","key":"3452_CR8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-134-2-200101160-00015","volume":"134","author":"M Selman","year":"2001","unstructured":"Selman M, King TE, Pardo A (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134(2):136\u2013151","journal-title":"Ann Intern Med"},{"issue":"2","key":"3452_CR9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","volume":"349","author":"L Wollin","year":"2014","unstructured":"Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B (2014) Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 349(2):209\u2013220","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"3452_CR10","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","volume":"45","author":"L Wollin","year":"2015","unstructured":"Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M (2015) Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 45(5):1434\u20131445","journal-title":"Eur Respir J"},{"issue":"12","key":"3452_CR11","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","volume":"365","author":"L Richeldi","year":"2011","unstructured":"Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Kl\u00fcglich M, du Bois RM (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365(12):1079\u20131087","journal-title":"N Engl J Med"},{"issue":"22","key":"3452_CR12","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le MF, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR, INPULSIS Trial Investigators (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 (22):2071\u20132082","journal-title":"N Engl J Med"},{"key":"3452_CR13","unstructured":"Boehringer Ingelheim (2017) OFEV\u00ae (nintedanib) capsules, for oral use; Prescribing information, revised: 08\/2017. \n                        http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Ofev\/ofev.pdf\n                        \n                    . Accessed 30 Aug 2017"},{"key":"3452_CR14","unstructured":"European Medicines Agency (2014) Committee for Medicinal Products for Human Use (CHMP) Assessment Report for Ofev(nintedanib), 20 November 2014. \n                        http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003821\/WC500182476.pdf\n                        \n                    . Accessed 12 May 2017"},{"issue":"1","key":"3452_CR15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1078-0432.CCR-09-0694","volume":"16","author":"K Mross","year":"2010","unstructured":"Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, Strecker R, Henning J, Gaschler-Markefski B, Stopfer P, de Rossi L, Kaiser R (2010) Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 16(1):311\u2013319","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3452_CR16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/00498254.2010.545452","volume":"41","author":"P Stopfer","year":"2011","unstructured":"Stopfer P, Rathgen K, Bischoff D, Ludtke S, Marzin K, Kaiser R, Wagner K, Ebner T (2011) Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 41(4):297\u2013311","journal-title":"Xenobiotica"},{"key":"3452_CR17","unstructured":"Boehringer Ingelheim (2006) Safety and pharmacokinetics\/bioavailability of a single dose of 150 mg BIBF 1120 administered as soft gelatine capsules with and without food to healthy male volunteers in an open, randomised, intra-individual crossover comparison design, Phase I trial. Trial No. 1199.17. \n                        http:\/\/www.trials.boehringer-ingelheim.com\/public\/trial_results_documents\/1199\/1199.17_U06-1411-02.pdf\n                        \n                    . Accessed 12 May 2017"},{"issue":"5","key":"3452_CR18","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1183\/09031936.00198013","volume":"45","author":"T Ogura","year":"2015","unstructured":"Ogura T, Taniguchi H, Azuma A, Inoue Y, Kondoh Y, Hasegawa Y, Bando M, Abe S, Mochizuki Y, Chida K, Kluglich M, Fujimoto T, Okazaki K, Tadayasu Y, Sakamoto W, Sugiyama Y (2015) Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 45(5):1382\u20131392","journal-title":"Eur Respir J"},{"issue":"11","key":"3452_CR19","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/jcph.752","volume":"56","author":"C Dallinger","year":"2016","unstructured":"Dallinger C, Trommeshauser D, Marzin K, Liesener A, Kaiser R, Stopfer P (2016) Pharmacokinetic properties of nintedanib in healthy volunteers and patients with advanced cancer. J Clin Pharmacol 56(11):1387\u20131394","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"3452_CR20","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s10637-013-9962-7","volume":"31","author":"T Eisen","year":"2013","unstructured":"Eisen T, Shparyk Y, Macleod N, Jones R, Wallenstein G, Temple G, Khder Y, Dallinger C, Studeny M, Loembe AB, Bondarenko I (2013) Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Invest New Drugs 31(5):1283\u20131293","journal-title":"Invest New Drugs"},{"key":"3452_CR21","unstructured":"Boehringer Ingelheim (2013) Relative bioavailability of nintedanib given alone and in combination with ketoconazole at steady state in healthy male volunteers (an open-label, randomised, two-way cross-over clinical Phase I study). Trial No. 1199.161. \n                        http:\/\/www.trials.boehringer-ingelheim.com\/public\/trial_results_documents\/1199\/1199.161_U13-1925-01-DS_DR.pdf\n                        \n                    . Accessed 12 May 2017"},{"key":"3452_CR22","unstructured":"Boehringer Ingelheim (2013) Relative bioavailability of a single oral dose of nintedanib given alone and in combination with multiple oral doses of rifampicin in healthy male volunteers (an open-label, two-period, fixed-sequence clinical Phase I trial). Trial No. 1199.162. \n                        http:\/\/www.trials.boehringer-ingelheim.com\/public\/trial_results_documents\/1199\/1199.162_U13-1478-01-DS_DR.pdf\n                        \n                    . Accessed 12 May 2017"},{"issue":"6","key":"3452_CR23","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/annonc\/mdq618","volume":"22","author":"M Reck","year":"2011","unstructured":"Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P, von Pawel J (2011) A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 22(6):1374\u20131381","journal-title":"Ann Oncol"},{"issue":"2","key":"3452_CR24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75(2):85\u201394","journal-title":"Comput Methods Programs Biomed"},{"issue":"3","key":"3452_CR25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79(3):241\u2013257","journal-title":"Comput Methods Programs Biomed"},{"issue":"5","key":"3452_CR26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1634\/theoncologist.2008-0284","volume":"14","author":"DA Yardley","year":"2009","unstructured":"Yardley DA (2009) Proactive management of adverse events maintains the clinical benefit of ixabepilone. Oncologist 14(5):448\u2013455","journal-title":"Oncologist"},{"key":"3452_CR27","unstructured":"Bristol-Myers Squibb (2016) Ixempra Kit (ixabepilone) for injection, for intravenous infusion only. Prescribing information, revised: 01\/2016. \n                        http:\/\/ixempra.com\/downloads\/full_pi.pdf\n                        \n                    . Accessed 12 May 2017"},{"issue":"10","key":"3452_CR28","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-11-2873","volume":"18","author":"PM LoRusso","year":"2012","unstructured":"LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, Hamilton A, Dowlati A, Mani S, Rudek MA, Takimoto CH, Neuwirth R, Esseltine DL, Ivy P (2012) Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res 18(10):2954\u20132963","journal-title":"Clin Cancer Res"},{"key":"3452_CR29","unstructured":"Food and Administration Drug (2003) Guidance for Industry. Pharmacokinetics in patients with impaired hepatic function: Study design, data analysis, and impact on dosing and labeling. \n                        https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm072123.pdf\n                        \n                    . Accessed 12 May 2017"},{"issue":"12","key":"3452_CR30","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1158\/1078-0432.CCR-06-2385","volume":"13","author":"TW Synold","year":"2007","unstructured":"Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Kaufman BM, Ivy P (2007) Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 13(12):3660\u20133666","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3452_CR31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31\u201341","journal-title":"Nephron"},{"issue":"2","key":"3452_CR32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151","journal-title":"AAPS J"},{"issue":"5","key":"3452_CR33","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4155\/tde.11.19","volume":"2","author":"JA Y\u00e1\u00f1ez","year":"2011","unstructured":"Y\u00e1\u00f1ez JA, Remsberg CM, Sayre CL, Forrest ML, Davies NM (2011) Flip-flop pharmacokinetics\u2014delivering a reversal of disposition: challenges and opportunities during drug development. Ther Deliv 2(5):643\u2013672","journal-title":"Ther Deliv"},{"key":"3452_CR34","unstructured":"Boehringer Ingelheim (2015) Pharmacokinetics, safety and tolerability of nintedanib single oral dose in male and female patients with different degrees of hepatic impairment (Child-Pugh classification A and B) as compared with nintedanib administration to male and female healthy subjects (a non-blinded, parallel group study of Phase I), Phase I trial. Trial No. 1199.200. \n                        http:\/\/www.trials.boehringer-ingelheim.com\/public\/trial_results_documents\/1199\/1199.200_c03149997-01_DR.pdf\n                        \n                    . Accessed 12 May 2017"},{"issue":"10","key":"3452_CR35","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1158\/1078-0432.CCR-09-2944","volume":"16","author":"PM Ellis","year":"2010","unstructured":"Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S, Hanna N (2010) Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 16(10):2881\u20132889","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3452_CR36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/JTO.0000000000000395","volume":"10","author":"I Okamoto","year":"2015","unstructured":"Okamoto I, Miyazaki M, Takeda M, Terashima M, Azuma K, Hayashi H, Kaneda H, Kurata T, Tsurutani J, Seto T, Hirai F, Konishi K, Sarashina A, Yagi N, Kaiser R, Nakagawa K (2015) Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer. J Thorac Oncol 10(2):346\u2013352","journal-title":"J Thorac Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3452-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3452-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3452-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T02:31:16Z","timestamp":1515033076000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3452-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3452"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3452-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,8]]}}}